Equity Field Notes from temporal sources

[DanWebzster]

BCRX has 3 important milestones remaining in 2020:

1) Preliminary Galdesivir Ph I data of wuflu patients in Brazil
2) Additional Ph I dose escalation results in both PNH treatment
naive and PNH patients taking CS inhibitors
3) 12/3 PDUFA

Galdesivir has worked in animal studies against other RNA viruses including Ebola, Marburg, Yellow Fever and Zika

BCX9030 data in PNH (Paroxysmal Nocturnal Hemoglobinuria) is due Q3/2020. This indication is a competitive space (ALXN , APLS); but, relative success in PNH could be a gateway to larger complement indications such as C3 glomerulopathy.

BCRX raised 140M 5/20 to bring cash to 225M EOQ1/20.

Cash burn for 2020 is estimated to be 125-150M

Cash runway thru mid 2021.

Assuming Berotralstat approval, at least one more cap raise will be necessary to bring BCRX to break even.